These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 4276463)

  • 1. Comparison of human plasma fibrinogen subfractions and early plasmic fibrinogen derivatives.
    Mosesson MW; Galanakis DK; Finlayson JS
    J Biol Chem; 1974 Jul; 249(14):4656-64. PubMed ID: 4276463
    [No Abstract]   [Full Text] [Related]  

  • 2. Structure of plasmic degradation products of human fibrinogen. Fibrinopeptide and polypeptide chain analysis.
    Budzynski AZ; Marder VJ; Shainoff JR
    J Biol Chem; 1974 Apr; 249(7):2294-302. PubMed ID: 4131967
    [No Abstract]   [Full Text] [Related]  

  • 3. The NH2-terminal amino acids of the fibrinogen degradation products. Implications for fibrinogen structure.
    Marder VJ; Budzynski AZ
    Thromb Diath Haemorrh Suppl; 1973; 56():127-35. PubMed ID: 4281939
    [No Abstract]   [Full Text] [Related]  

  • 4. The synthetic peptide Gly-Pro-Arg-Pro-amide limits the plasmic digestion of fibrinogen in the same fashion as calcium ion.
    Yamazumi K; Doolittle RF
    Protein Sci; 1992 Dec; 1(12):1719-20. PubMed ID: 1304901
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasmic degradation of human fibrinogen. III. Molecular model of the plasmin-resistant disulfide knot in monomeric fragment D.
    Furlan M; Kemp G; Beck EA
    Biochim Biophys Acta; 1975 Jul; 400(1):95-111. PubMed ID: 125109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fate of fibrinopeptides in the reaction between human plasmin and fibrinogen.
    Lahiri B; Shainoff JR
    Biochim Biophys Acta; 1973 Mar; 303(1):161-70. PubMed ID: 4267201
    [No Abstract]   [Full Text] [Related]  

  • 7. Human fibrinogen heterogeneities. I. Structural and related studies of plasma fibrinogens which are high solubility catabolic intermediates.
    Mosesson MW; Finlayson JS; Umfleet RA; Galanakis D
    J Biol Chem; 1972 Aug; 247(16):5210-9. PubMed ID: 4262568
    [No Abstract]   [Full Text] [Related]  

  • 8. Degradation of fibrinogen by plasmin: physicochemical characteristics and their correlation to antithrombic activity.
    Triantaphyllopoulos E
    Thromb Diath Haemorrh Suppl; 1973; 56():91-112. PubMed ID: 4281941
    [No Abstract]   [Full Text] [Related]  

  • 9. Subunit structure of fragment D from fibrinogen and cross-linked fibrin.
    Pizzo SV; Taylor LM; Schwartz ML; Hill RL; McKee PA
    J Biol Chem; 1973 Jul; 248(13):4584-90. PubMed ID: 4198060
    [No Abstract]   [Full Text] [Related]  

  • 10. The in vivo behavior of the terminal derivatives of fibrinogen and fibrin cleaved by plasmin.
    Catanzaro A; Edgington TS
    J Lab Clin Med; 1974 Mar; 83(3):458-66. PubMed ID: 4272970
    [No Abstract]   [Full Text] [Related]  

  • 11. Heterogeneity of bovine fibrinogen and fibrin.
    Mosher DF; Blout ER
    J Biol Chem; 1973 Oct; 248(19):6896-903. PubMed ID: 4745449
    [No Abstract]   [Full Text] [Related]  

  • 12. The essential covalent structure of human fibrinogen evinced by analysis of derivatives formed during plasmic hydrolysis.
    Mosesson MW; Finlayson JS; Galanakis DK
    J Biol Chem; 1973 Nov; 248(22):7913-29. PubMed ID: 4127218
    [No Abstract]   [Full Text] [Related]  

  • 13. Human fibrinogen free of factor XIII: the pursuit of biological zero.
    Finlayson JS
    Ann N Y Acad Sci; 1972 Dec; 202():149-54. PubMed ID: 4629549
    [No Abstract]   [Full Text] [Related]  

  • 14. Protective effect of divalent cations in the plasmin degradation of fibrinogen.
    Dang CV; Bell WR; Ebert RF; Starksen NF
    Arch Biochem Biophys; 1985 May; 238(2):452-7. PubMed ID: 3158281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmic degradation of human fibrinogen. IV. Identification of subunit chain remnants in fragment Y.
    Furlan M; Seelich T; Beck EA
    Biochim Biophys Acta; 1975 Jul; 400(1):112-20. PubMed ID: 125108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic identification of the cleavage products from the A alpha- and B beta-chains in the early stages of plasmin digestion of fibrinogen.
    Liu CY; Sobel JH; Weitz JI; Kaplan KL; Nossel HL
    Thromb Haemost; 1986 Aug; 56(1):100-6. PubMed ID: 2946092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of human plasminogen by urokinase. Partial characterization of a pre-activation peptide.
    Walther PJ; Steinman HM; Hill RL; McKee PA
    J Biol Chem; 1974 Feb; 249(4):1173-81. PubMed ID: 4273519
    [No Abstract]   [Full Text] [Related]  

  • 18. The alpha(E)C domain of human fibrinogen-420 is a stable and early plasmin cleavage product.
    Applegate D; Steben LS; Hertzberg KM; Grieninger G
    Blood; 2000 Apr; 95(7):2297-303. PubMed ID: 10733499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmic degradation of human fibrinogen. I. Structural characterization of degradation products.
    Furlan M; Beck EA
    Biochim Biophys Acta; 1972 May; 263(3):631-44. PubMed ID: 4260762
    [No Abstract]   [Full Text] [Related]  

  • 20. A new apoprotein of human plasma very low density lipoproteins.
    Shelburne FA; Quarfordt SH
    J Biol Chem; 1974 Mar; 249(5):1428-33. PubMed ID: 4361735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.